Tranexamic Acid and Postoperative Bleeding in Rhinoplasty: Insights from a Nationwide EHR Study

Objective: Tranexamic acid (TXA) is widely used in rhinoplasty to minimize intraoperative bleeding and improve visualization; however, its effect on postoperative bleeding remains unclear. This study aimed to evaluate whether intravenous TXA reduces postoperative bleeding in patients undergoing primary or secondary rhinoplasty. Methods: A retrospective cohort study was performed using the TriNetX national research database to identify patients who underwent primary (CPT 30400, 30410, 30420) or secondary (CPT 30430, 30435, 30450) rhinoplasty from 2010 to 2023. Patients were grouped based on perioperative usage of intravenous TXA. Propensity score matching adjusted for demographics and coagulation disorders (ICD-10 D65–D69). The primary outcome was postoperative bleeding, including epistaxis, within one month of surgery. Results: Among 2586 patients who met inclusion criteria, 1293 (50%) received TXA. TXA recipients had a higher prevalence of bleeding risk factors, including prior use of antihemorrhagic medications (5.9% vs. 1.8%, p < 0.0001) and prolonged prothrombin time (20% vs. 16.1%, p = 0.032). TXA patients more frequently underwent concurrent septoplasty (29.7% vs. 21%, p < 0.0001). There were no significant differences observed in postoperative epistaxis or bleeding between cohorts. Similar postoperative bleeding rates despite these higher-risk characteristics suggest that TXA may have benefit in the mitigation of elevated bleeding risk in the treated cohort. Conclusions: TXA is preferentially administered to patients at higher risk of bleeding and during more complex, vascular procedures prone to increased blood loss. Prospective studies are needed to directly test whether TXA normalizes bleeding risk in higher-risk rhinoplasty patients.